Various molecules expressed on the surface of platelets have been shown to mediate the protective or deleterious role of these cells in immuno-inflammatory mechanisms. Increasing evidence points to the involvement of the cell adhesion molecules, gpIlb-IIIa, P-selectin, CD31, LFA-1, and CD36 in the interaction between platelets and endothelial cells as well as other cell types. The possible role of these molecules in the ability of platelets to support endothelium and to protect against tumour necrosis factor mediated cytolysis or parasitic invasion are reviewed. The involvement of platelets as effectors of tissue damage in cerebral malaria, lipopolysaccharide induced pathology, and pulmonary fibrosis is also discussed. This has then been extended to include the intercellular mechanisms underpinning their pathogenic role in metastasis, transplant rejection, stroke, brain hypoxia, and related conditions. A better understanding of the complex regulation and hierarchical organisation of these various platelet adhesion molecules may prove useful in the development of new approaches to the treatment of such diseases.
This review outlines the role of a number of key surface molecules expressed by platelets in various immuno-inflammatory mechanisms. As platelets exhibit a plethora of surface as well as intracellular molecules thought to be implicated in such functions, we found it necessary to restrict this overview to those considered most important in these cellular processes. We chose those involved in adhesion, without any attempt to establish a hierarchy of importance in pathogenic mechanisms (fig 1) . Several other pathways of cell-cell communication between platelets and various other cell types, such as those implicated in haemostasis, have been reviewed elsewhere. ' Much of the information currently available on phenomena related to platelet adhesion concerns platelet-zendothelial cell interactions, platelet-platelet aggregation, and thrombus formation. Only recently, have the molecular mechanisms underlying the interaction between platelets and leucocytes become the topic of intense research. Descriptions of the functions of adhesion molecules as regulators of leucocyte trafficking have provided a new stimulus for interesting investigations into the biology of leucocyte adhesion. Adhesion phenomena have also gained importance in broadening our understanding of tumour cell dissemination and extravasation. As platelets are abundant in the bloodstream and exhibit such marked adhesive properties, we consider that alterations in the expression of specific adhesion molecules may play an important part in mediating their protective or pathogenic roles in the body. With this in mind, we have collated data from both clinical and experimental studies on this aspect of platelet biology.
Surface molecules mediating platelet interactions with other cell types GLYCOPROTEIN IIb-IIIa Platelet anchorage and signalling is mainly regulated by the integrin gpIIb-IIIa (CD4 1 a,b/ CD61, aIIb-P3, fibrinogen receptor).2 3 Blocking the gpIIb-IIIa receptor using monoclonal antibodies or small peptides such as Asp-GlyArg (RGD), which competes with the fibrinogen binding site, significantly inhibit activated platelet adhesion to activated endothelium. 4 GpIIb-IIIa is also a central molecule in the mediation of platelet aggregation. Fibrinogen binding to gpIIb-IIIa plays a pivotal role in formation of platelet thrombi by providing molecular bridges spanning platelets and mediating intracellular signalling triggered by this interaction. Fibrinogen binding to gplIb-IIIa ensues in response to external signals generated at the site of vascular injury. These external signals lead to a conformational change of the gpIIb-IIIa induced by inside-out signalling mediated by intraplatelet signal transducers. The structure and functions of gpIIb-IIIa have been reviewed recently. 5 this signalling process.3 As a consequence of platelet activation, conformational changes and fibrinogen binding, gpIIb-IIIa becomes associated with the cytoskeleton. The cytoplasmic sequences of both gpIIb and gpIIIa directly bind to talin, a molecule connecting to the cytoskeleton. 9 The expression of gpIIb-IIIa is unique to the megakaryocyte lineage. Besides its predominant role in platelet-platelet aggregation, it also allows their aggregation on to heterologous cells,"0 notably on to polymorphonuclear (neutrophils) leucocytes. 112 In addition, fibrinogen receptors have also been reported to be expressed on some tumour cells.'3 '4 However, other mechanisms are involved in interactions between platelets and various cell types, notably that of thrombospondin with its receptor,'5 or with other binding partners such as CD36'6 or the vitronectin receptor. '5 The interactions between gplIb-IIIa and its ligands can be abrogated using several types of inhibitor. Ligands for gpIIb-IIIa comprise fibrinogen, of which RGD is a recognition sequence, fibronectin, vWT, thrombospondin, and vitronectin." Several types of gpIIb-IIIa antagonists have been described and characterised both in vitro and in vivo. These include small peptides competing with recognition sequences (such as RGD), pentamidin,'8 SKF 107260, '9 DMP728,'0 SC-49992,2
Ro-43-8857,2' disintegrins, a family of snake venom derived proteins,23 and disagregin. '4 Additionally, platelet adhesion to fibronectin can be inhibited by direct binding ofheparin to the fibronectin surface. 25 GpIIb-IIIa can also be antagonised indirectly by interfering with the binding of vWF to gplb. VCL, a recombinant monomeric fragment of vWT, containing the gpIb binding domain, has such properties.26 Finally, it has also been demonstrated that platelet aggregation is inhibited by fibrinolysis." Tissue-type plasminogen activator (tPA) induces thrombolysis in coronary arteries through the local generation of plasmin. Plasmin also proteolyses gpIb and plasma vWF. Consequently, tPA inhibits platelet aggregation in response to pathological shear stress by altering the multimeric composition of vWF.
P-SELECTIN P-selectin (CD62-P), originally described as PADGEM/GMP 140, is an a granule membrane protein that is expressed on the platelet surface on activation.282' Antibodies to P-selectin can inhibit platelet aggregation, suggesting an active role of P-selectin in plateletplatelet interactions. 30 In addition, P-selectin mediates platelet and leucocyte rolling on stimulated endothelium, as shown by the impairment of this phenomenon in mice genetically deficient for this molecule.3' This interaction requires endothelial rather than platelet P-selectin. As platelet rolling is independent of platelet activation, this suggests a constitutive expression of a P-selectin ligand on platelets. The P-selectin glycoprotein ligand-I (PSGL-1)"2 found on myeloid cells is also expressed on human platelets.33 Furthermore, it has been shown that activated platelets can signal chemokine synthesis by monocytes via PSGL-1 on the latter cells.)4 P-selectin is also crucial in neutrophil adhesion to damaged endothelium under flow conditions. 35 The finding that neutrophils adhere predominantly to platelets attached to the extracellular matrix, and not directly to endothelial cells, supports the hypothesis that platelet adhesion to an injured vessel wall leads to P-selectin expression by platelets, thus mediating leucocyte co-localisation. Studies with specific antibodies showed that platelet dependent neutrophil adhesion was selectin mediated. Inhibition of P-selectin caused a marked inhibition of adhesion at high sheat stress, whereas the role of leucocyte L-selectin was less pronounced. Such platelet mediated leucocyte delivery to endothelial cells has been documented using intravital microscopy. 36 It has also been shown that granulocytes enhance tissue factor expression on monocytes via platelet interaction and a P-selectin dependent pathway. 37 Circulating 51 The relevance of these findings in humans remains the subject of much debate. Monoclonal antibodies against the LFA-1 subunit of the leucocyte adherence complex, CD18, inhibited the binding of bone marrow megakaryocytes to HUVEC.5" The low and variable expression of LFA-1 (that can be increased upon exposure to thrombin) has been shown on human platelets.53 However, anti-LFA-1 antibodies do not interfere with mononuclear leucocyte induced inhibition of platelet aggregation.54 This is evidence against an involvement of platelet LFA-1 in the aggregation mechanism. Although there is no evidence for ICAM-1 expression on human platelets, it is notable that these cells express ICAM-2 and are able to bind T lymphocytes via this receptor.55 CD36 (gpIV) CD36 is expressed on platelets as well as on monocytes and endothelial cells.56 The numerous functional aspects of this cell surface glycoprotein, as well as its various ligands, have -been reviewed recently. 57 Blocking experiments with monoclonal antibodies indicated that CD36 mediates platelet aggregation58 but not the adhesion of platelets to collagen and subendothelial matrix.59 CD36 binds to thrombospondin, the role of which in platelet adhesion remains controversial. Both adhesive and anti-adhesive properties have been attributed to this molecule. In contrast to the extensive platelet spreading observed on fibronectin at all shear rates, platelet spreading on thrombospondin occurred only sporadically and at high shear rates. GpIa-IIa, gpIIb-IIIa, CD36, and the vitronectin receptor, which are all proposed platelet receptors for thrombospondin, are not solely responsible for platelet adhesion to thrombospondin. CD36 may thus play a dual role in adhesive processes in vivo: it may function in conjunction with other adhesive proteins to maintain optimal platelet adhesion at various shear rates; and it may serve as a modulator of cellular adhesive functions under specific microenvironmental conditions.60 The Investigations in murine models of cerebral malaria suggest a new effector mechanism of TNF induced endothelial cells lesion-the role for TNF in cerebral malaria (both human and murine) has been reviewed. 87 It consists of increased adhesion of platelets to the surface of endothelial cells and their subsequent fusion into the cytoplasm of endothelial cells. In the mouse system, platelets express LFA-1 on their surface, therefore, they were envisaged in the pathogenesis of cerebral malaria. Otherwise there was no clear explanation for the dramatic protective effect of anti-LFA-1 monoclonal antibody (MoAb), even when this MoAb was given shortly before death.88 89 The following findings suggest that the platelet is a critical effector of the neurovascular injury in cerebral malaria.48 First, investigation of brains from mice with cerebral malaria using electron microscopy revealed that during cerebral malaria platelets adhere to and probably damage brain endothelial cells. Interestingly, platelets have also been found in brain vessels in fatal cases of human cerebral malaria.90 Second, radiolabelled platelet distribution studies indicated that platelets significantly sequestered in the brain and lung vasculature during cerebral malaria. Non-cerebral malaria was not associated with cerebral sequestration of platelets. Third, treatment in vivo with anti-LFA-1 MoAb selectively abrogated the cerebral sequestration of platelets; moreover, this correlated with prevention of the neurological syndrome. The a (CD11a) and, to a lesser extent, the f (CD1 8) chains of integrin LFA-1 were found to be expressed on mouse platelet membranes. Finally, animals with malaria rendered thrombocytopenic were significantly protected against cerebral malaria, further indicating that platelets are central to the pathogenesis of cerebral malaria.
Thus, a CD11a dependent interaction between platelets and endothelial cells appears pivotal to microvascular damage. Microvascular lesions of cerebral malaria would thus depend on platelet mediated, TNF induced endothelial cell damage (fig 2) .9' These data suggest a novel mechanism of action for anti-LFA-1 MoAb in the neurovascular complications of murine malaria and illustrate an unexpected role for platelets in vascular pathology.
The mechanism of platelet fusion with endothelial cells may be the same in physiological and pathological situations, with the main difference between these two conditions being the intensity of the phenomenon. Morphological data should orientate towards the precise mechanisms involved, which remain incompletely understood. In experimental cerebral malaria, cerebral capillaries and venules contain platelets in dense contact to the endothelium or fusing to damaged brain endothelial cells. Endothelial cells are damaged, interrupted, and show the presence of dense and a granules, suggesting the fusion between platelets and endothelium. Monocytes also adhere to brain endothelial cells but, unlike platelets, do not show any membrane fusion and the endothelium is unaffected. These morphological features of platelet-endothelium interactions are reminiscent of those reported in the context of the endothelium supporting role of platelets.69.71 TNF induced microvascular injury might be caused by an exaggeration of the fusion phenomenon caused by ICAM-1 upregulation on endothelial membranes. Recently, a particular role for membrane bound TNF has been demonstrated in ICAM-1 upregulation, and thereby in cerebral malaria pathogenesis.9" Platelets carrying the LFA-1 molecule would then be bound in higher amounts on these endothelial surfaces, and cell fusion would occur at a higher rate (fig 2) . In humans, other ligand-receptor pairs, implicating P-selectin or CD36, could participate in this phenomenon.
The involvement of platelets as effectors of vascular lesions may not be restricted to experimental pathology. In humans, cerebral malaria has been associated with accumulation of platelets in cerebral microvessels, although the nature of the platelet-endothelial interactions in this setting have not been investigated in detail. 90 49 In both experimental conditions, it was found that platelet depletion in vivo (by either poly-or monoclonal antiplatelet antibody treatment) afforded significant protection. Furthermore, in the local reaction, platelets were found to be localised in the dermal venules before haemorrhage occurred. Anti-LFA-1 and anti-ICAM-l MoAbs prevented both platelet localisation and haemorrhagic necrosis. Thus, at least in the local reaction, the combined effects of LPS and TNF result in a binding of platelets to microvascular endothelium via their f2 integrins, which seems necessary for the development of the haemorrhagic necrosis.
Indirect evidence for a role of platelets in LPS or TNF pathology has been provided by experiments demonstrating the protective capacity of a(l)-acid glycoprotein.'0' This typical acute phase protein protects mice from lethal shock induced by TNF or endotoxin. The protection is observed both in normal and in galactosamine sensitised mice. Complete inhibition of all TNF induced metabolic changes was observed: fall in body temperature, release of liver transaminases, enhanced clotting time, and mortality. As a(l)-acid glycoprotein is known to inhibit platelet aggregation, its protective efficacy in this setting may suggest a pathogenic role of platelets.
Other illustrations of a role of platelets have been obtained in a sheep model of endotoxic shock.'08 Platelet sequestration in the lungs and liver of LPS challenged animals was more efficiently blocked by the dual cyclooxygenase and lipoxygenase inhibitor ketoprofen than by the classic cyclooxygenase inhibitor aspirin. In sheep sepsis, pentoxifylline, provided it was given before LPS, was also able to reduce pulmonary and hepatic platelet sequestration."'' In a model of porcine sepsis, platelets were found occluding the hepatic vasculature, and this as well as other ultrastructural changes were prevented by the dopaminergic and 12 adrenergic receptor agonist dopexamine,'09 raising the possibility that this molecule, in addition to its systemic circulatory effects, can also modulate platelet-endothelial interactions.
The role of platelet membrane glycoproteins and platelet-leucocyte adhesion was studied in patients with sepsis and multiple organ failure." 0 Flow cytometry was used to examine platelet membrane expression of various adhesion molecules on circulating platelets and the appearance of platelet specific antigen (gp IIb, CD41) on leucocytes as an index of plateletleucocyte adhesion. The results were compared with severity of disease and according to outcome in patients. In septic patients fibrinogen receptor activity on platelets was significantly above normal values. When multiple organ failure was present, thrombospondin surface expression on circulating platelets also increased significantly. Concomitantly, platelet-leucocyte adhesion was increased in sepsis and decreased in patients with multiple organ failure. Significant lower numbers of circulating platelet-leucocyte aggregates occurred in non-survivors. Thus, sepsis is associated with increased surface-expression of platelet adhesion molecules and increased occurrence of circulating platelet-leucocyte e mechanism complement depleted rat recipients of guinea e metastasis. pig cardiac xenografts, a specific gpIIb-IIIa d by 12(S)-antagonist (SDZ GPI 562) significantly inte of arachi-creased graft survival. Immunohistological F which was studies showed little effect of this antagonist on cell-platelet-platelet aggregation or activation and no effect twever, in the on fibrin deposition. However, the combination of high doses of gpIIb-IIIa antagonist and complement depletion by cobra venom factor resulted in a significant decrease in intragraft platelet aggregation, P-selectin expression, and leucocyte infiltration compared with decomplementation alone. Thus, the diminution of intragraft platelet microthrombi formation and leucocyte infiltration suggests an important role for platelet dependent mechanisms in leucocyte recruitment during delayed xenograft rejection. platelets or an effect of platelets on endothelium. Although the former alternative cannot be totally ruled out, the observations seem to fit the hypothesis that progressive endothelial damage can result from increasing activation and degranulation of overlying platelets.
Other models have shown that on cerebral ischaemia reperfusion, adhesion molecules such as P-selectin and ICAM-1 are upregulated on microvessels in the ischaemic zone, leading to leucocyte adhesion and activation, but the precise role of platelets in this setting remains to be investigated. '25 Conclusions Relatively few studies have directly addressed the role of platelets in inflammation. During the past decade, adhesion molecules have been the focus of intense research, with much importance given to cell-cell interactions; however, their complex role in the activation pathways of haemostasis and inflammation require further study. Ofparticular interest will be investigations on the interplay of platelet surface molecules and leucocyte integrins or selectins and endothelial cell adhesion molecules.
With respect to the activation of cells, a major contribution was the finding that the pairing of adhesion molecules in cell-cell interactions facilitates the signalling into both cells to mediate, in part, cell activation. The signals can either be mediated via the adhesion molecules serving as membrane receptors in heterophilic or homophilic interactions or via the respective membrane associated ligands. Furthermore, soluble ligands can induce signalling via adhesion molecule-receptor aggregation or conformational changes after ligand binding. Such signalling, which leads to activation of cells, can also induce the release of biologically important mediators from platelets. As platelets are so numerous and degranulation is a rather rapid event this may represent a very effective biological response. Localisation by adhesion in some microvascular beds (such as at inflammatory sites) provides an ideal means of restricting the effect to the site of interest.
A role for platelets can be predicted in some types of hypersensitivity reactions, and notably immune complex mediated diseases. The involvement of platelets in the pathogenesis of these conditions should be revisited. Differences between animal (rabbit or mouse) and human platelets should also be considered. Based on physiological and pathological relevance in vivo, one should design experiments aiming at a better definition of the hierarchy of importance of various platelet adhesion molecules in selected biological effects. Exploiting such findings should be useful for developing new therapeutic approaches. 
